CliffBio
small molecule

APLENZIN

BUPROPION HYDROBROMIDE

Loss of exclusivityJune 2026latest FDA-listed patent expiry
CompanyBAUSCH HEALTH US LLC

Drug detail

Brand nameAPLENZIN
Active ingredientBUPROPION HYDROBROMIDE
Strength348MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2008
Marketing statusRX

Listed patents

PatentExpiresType
7569610June 2026use U-997
7662407June 2026product
7572935June 2026product
7585897June 2026product
7645802June 2026product
7671094June 2026product
7241805June 2026product
7649019June 2026product

More from BAUSCH HEALTH US LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

APLENZIN patent cliff — loss of exclusivity June 2026 | CliffBio